Policy & Regulation
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
9 June 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that it has entered an agreement to acquire Nuvalent Inc (NASDAQ:NUVL), a Boston-based clinical-stage biopharm...
Adcentrx Therapeutics' ADRX-0405 granted Chinese regulatory IND clearance to treat late-stage solid tumours
9 June 2026 - Adcentrx Therapeutics, a California-based clinical-stage biotechnology company advancing Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases,...
Argo Biopharma to present updated BW-20805 Phase II results at EAACI 2026 Congress
9 June 2026 - Argo Biopharmaceutical Co., Ltd., a China-based, clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Monday that it has been selected to present Phase II upda...
Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma
...
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
8 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that it has received European Commission approval for subcutaneous Sarclisa (isatuximab) for m...
Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide
8 June 2026 - Hangzhou Sciwind Biosciences Co Ltd, a China-based, commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, announce...